Biotech Co.* (Country/Symbol)

Pharma Co. (Country)

Type/Product Area

Disclosed Funding (M)

Terms/Details (Date)

Affitech (Norway)*

Nycomed Amersham Imaging (UK)

Research agreement for the discovery of fully human antibodies for imaging applications

ND

Affitech will receive milestone and royalty payments (8/20)

Aventis Pharmaceuticals Inc. (NYSE:AVE)

Ajinomoto Co. (Japan)

Licensing agreement to develop and market AVE8062

ND

Aventis receives rights to develop and market the product in exchange for certain milestone payments and royalty payments (7/12)

BioDiscovery Inc.*

Torrey Mesa Research Institute (subsidiary of Syngenta AG; Switzerland)

Site license agreement for BioDiscovery's Genesight software

ND

The software will be used for the analysis of gene expression data generated by the institute (8/28)

Biofrontera Pharmaceuticals AG (Germany)*

Janssen Pharmaceutica NV (unit of Johnson & Johnson; Belgium)

Research collaboration to explore the potential benefits of nicotinic modulation in the treatment of Alzheimer's disease

ND

The objective is to determine how Janssen's galantamine's (Reminyl) dual actions may contribute to the therapeutic benefit that Reminyl has demonstrated in clinical trials (8/27)

Boston Probes Inc.*

Diazyme Laboratories (subsidiary of General Atomics)

License and supply agreement for the development of single nucleotide polymorphism detection products that use peptide nucleic acid technology

ND

The terms of the agreement allow Diazyme to develop and market worldwide two PNA-based specific SNP kits to test for human blood coagulation disorders (7/30)

Coley Pharmaceutical Group Inc.*

Aventis Pharma AG (Germany)

Agreement for Coley's CpG immune modulators for use as asthma and allergic rhinitis therapeutics

ND

Aventis gains a worldwide license to CpG 9328, and up to three others; Coley gets milestone payments, and double-digit royalties on Aventis product sales (8/6)

Compugen Ltd. (Israel; CGEN)

Kyowa-Hakko Kogyo Co. Ltd. (Japan)

Agreement to license Gencarta, Compugen's annotated genome, transcriptome and proteome database and query tools

ND

Financial terms were not disclosed (7/17)

Compugen Ltd. (Israel; CGEN)

Novartis AG (Switzerland)

Agreement to use Compugen's technology services to accelerate identification of drug targets based on the analysis of fundamental gene and protein data

ND

Researchers will use DNA chip design provided by Compugen to detect which genes are expressed in various diseases (8/2)

Crucell NV (the Netherlands; CRXL)

Centocor Inc. (subsidiary of Johnson & Johnson)

Agreement for Centocor to develop and market Crucell's anticancer antibodies everywhere except Europe

ND

Centocor will pay Crucell annual milestone payments, as well as royalties; Crucell holds exclusive commercialization rights in Europe (8/16)

Curis Inc. (CRIS)

Elan Corp. plc (Ireland)

Joint venture to research and develop molecules that stimulate the hedgehog pathway

$28

Curis will receive about a $4M equity investment and another $10M to fund research and development; Elan will contribute a similar amount of money to Curis Newco, the joint venture (7/18)

Cypress Bioscience Inc. (CYPB)

bioMerieux Pierre Fabre (France)

License agreement to develop and sell any product with the compound milnacipran as an active ingredient, for the treatment of fibromyalgia syndrome and related chronic pain syndromes in the U.S. and Canada

ND

Cypress will pay an up-front payment; Pierre Fabre may receive milestone payments and royalties (8/1)

deCode Genetics Inc. (Iceland; DCGN)

F. Hoffmann-La Roche Ltd. (Switzerland)

Agreement to develop DNA-based diagnostics, predisposition screening products and point-of-care informatics 

$300

The letter of intent for the agreement was signed in March; the deal could mean as much as $300M for deCode (7/2)

Deltagen Inc. (DGEN)

Eli Lilly & Co. 

Agreement to use Deltagen's technology to evaluate and potentially develop and commercialize therapeutic secreted proteins

ND

The deal gives Lilly certain acquisition, co-promotion, co-marketing and profit-sharing options; Deltagen also will receive co-promotion, co-development and profit-sharing rights (8/2)

Demegen Inc. (OTC BB:DBOT)

Dow Chemical Co.

Research and licensing option agreement to design new products for use in industrial and commercial applications 

ND

Financial details were not disclosed (8/27)

diaDexus Inc.* 

Fujirebio Inc. (Japan)

Research and license collaboration to develop and sell cancer diagnostic tests in Japan 

ND

diaDexus will receive licensing fees and funding to support further research and development efforts for three years (8/9)

EpiVax Inc.*

Beckman Coulter Inc.

Alliance to discover, develop and commercialize products and services for the identification of biological sequences with potential for activating the immune system

ND

Beckman Coulter will market EpiVax epitope discovery services in the U.S., Canada and certain European countries (7/17)

Evotec OAI (Germany; Neuer Markt:EVT)

Pharmacia Corp.

Four-year contract under which Evotec will provide high-quality libraries for pharmaceutical screening

ND

Evotec will receive program and milestone fees on any product that comes out of the collaboration (8/21)

Exelixis Inc. (EXEL)

Bristol-Myers Squibb Co.

Collaboration focused on tumor suppression pathways

$200

Exelixis will identify and validate molecular targets that kill cancer cells, and Bristol-Myers will take up the validation work in humans; BMS will pay $5M up front, will buy 600,600 shares of Exelixis stock at $33.30 per share, and will pay $3M per year for at least three years; it also will pay milestones (7/18)

Exelixis Inc. (EXEL)

Elan Corp. plc (Ireland)

Agreement to make a high-throughput, small-molecule screening library that both companies can use

ND

In the three-year deal, Elan will pay Exelixis an undisclosed milestone fee, and more money as compounds are delivered (8/14)

FibroGen Inc.* 

Sankyo Co. Ltd. (Japan)

Three-year agreement to discover and develop treatments for fibrotic disorders to include diabetic nephropathy, retinopathy and forms of renal fibrosis, pulmonary fibrosis, organ transplant rejection, liver fibrosis and atherosclerosis

ND

FibroGen will receive an up-front payment, research funding and milestone payments; compounds developed for renal fibrosis, cardiovascular disease, diabetic retinopathy and hepatic fibrosis will be co-promoted in North America; FibroGen will receive royalties on sales outside of North America (9/11)

Gene Logic Inc. (GLGC)

UCB Research (division of UCB Pharma; Belgium)

Subscription agreement to the BioExpress Module of GeneLogic's GeneExpress suite

ND

UCB also purchased an exclusive license to additional asthma and allergy-related gene targets and associated gene expression data (9/6) 

Hyseq Inc. (HYSQ)

Kirin Brewery Co. Ltd. (Japan)

Research and development collaboration for discovering proteins and antibodies for diseases, including hematopoietic and inflammatory diseases

ND

Kirin will fund three years of research work; discoveries will be jointly owned and will be jointly developed and marketed with costs, efforts and revenues shared; Hyseq will have marketing rights in North America and Kirin will have marketing rights in Asia, New Zealand and Australia; rights will be shared for the rest of the world (8/16)

Illumina Inc. (ILMN)

GlaxoSmithKline plc (UK)

Agreement to provide single nucleotide genotyping services on a sample collection provided by GSK

ND

Illumina will use its BeadArray technology to determine the frequency of specified SNPs in the sample set (6/29)

Inhibitex Inc.* 

Wyeth Lederle Vaccines (unit of American Home Products Corp.)

Research and commercial partnership for the development of human vaccines targeting Staphyloccus aureus and Staphylococcus epidermidis

$23

Inhibitex granted an exclusive global license to its MSCRAMM protein technology for use in human vaccines; the company will receive up-front, milestone and research and development payments, as well as royalties (9/17)

InKine Pharmaceutical Co. Inc. (INKP)

Zeria Pharmaceutical Co. Ltd. (Japan)

Agreement for licensing rights to Visicol

$2.5

Zeria gained exclusive rights to Visicol in Japan, where it will develop the product as a bowel-cleansing agent; InKine will receive an up-front license fee of $500,000 and an additional $2M in fixed license fees upon reaching certain development milestones (9/4)

Isis Pharmaceuticals Inc. (ISIP)

Eli Lilly & Co. 

Agreement focused on Isis' antisense technology, specifically ISIS 3521 for non-small-cell lung cancer

$400

The deal includes a possible $200M in milestones, $100M in loans, $25M in up-front fees, research funding, and $75M in equity investments, as well as royalties; the companies also will collaborate to discover antisense drugs for metabolic and inflammatory disease (8/22)

Karo Bio AB (Sweden; SSE:KARO)

American Home Products Corp.

Agreement to focus on a drug to prevent and treat atherosclerosis

$100

Three-year agreement in which Karo would receive up to $100M in up-front payments, research and development funding, milestone payments and royalties, as well as an in-market bonus if certain sales goals are met (9/4)

Lexicon Genetics Inc. (LEXG)

GlaxoSmithKline plc (UK)

Agreement for a multiyear, nonexclusive sublicense to use its patented gene-targeting programs for GSK's internal research programs

ND

Lexicon will receive a one-time, up-front technology and license fee from GSK (8/15)

Lexicon Genetics Inc. (LEXG)

Merck & Co. Inc.

Licensing agreement for nonexclusive rights to its gene-targeting technologies

ND

Merck will use the technologies in its internal research programs (8/23)

LifeSpan BioSciences Inc.*

Sanofi-Synthelabo (France)

Subscription agreement for LifeSpan's database of information on the expression and localization of G protein-coupled receptors

ND

The contract calls for the number of GPCRs in the database to double from 160 to 320 (9/4)

MacroMed Inc.* 

Novartis Pharma AG (Switzerland)

Multidrug feasibility agreement for ReGel 

ND

Novartis gains access to MacroMed's controlled-release technology, ReGel (8/20)

Memory Pharmaceuticals Corp.*

Bayer AG (Germany)

MEM 1003

ND

Companies signed an exclusive worldwide license agreement for the rights to commercialize and market MEM 1003 for dementia; Memory will pay Bayer royalties, in addition to up-front and milestone payments (9/11)

Microbiotix Inc.*

Nissin Food Products Co. Ltd. (Japan)

Exclusive worldwide rights agreement to license a series of antiviral compounds

ND

One of the compounds, NMSO3, is an inhibitor of respiratory syncytial virus and adenoviruses (7/25)

Microcide Pharmaceuticals Inc. (MCDE)

NAEJA Pharmaceutical Inc. (Canada)

Research and license agreement to develop and commercialize drugs based on NAEJA's azole antifungals and Microcide's fungal efflux pump inhibitor leads 

ND

Microcide gains exclusive rights to develop and commercialize compounds based on NAEJA's proprietary azoles; Microcide will make milestone payments to NAEJA, as well as royalty payments (7/12)

Modex Therapeutics Ltd. (Switzerland; SWX:MDXN)

Serono SA (Switzerland)

Agreement for the engineering of a cell line for the production of a protein of commercial interest

CHF1 (US$0.59)

The two-year program will be entirely funded by Serono with Modex earning milestone fees of up to CHF1M (US$585, 133) and a percentage of future income derived from the sale of products based on the expressed protein (8/6)

M-phasys GmbH (Germany)*

Bayer AG (Germany)

Two-year collaborative agreement to discover active ingredients acting on membrane protein targets

ND

M-phasys will use its M-Fold technology to develop assay systems for high-throughput screening (7/10)

NeoGenesis Inc.

Mitsubishi-Tokyo Pharmaceuticals Inc. (Japan)

Agreement in which NeoGenesis will generate leads from a target supplied by Mitsubishi 

ND

NeoGenesis will receive discovery payments as well as milestones and midrange single-digit royalties (8/15)

NeoOncoRx Inc. (subisidary of NeoTherapeutics Inc.; NEOT)

Johnson Matthey plc (UK)

Agreement for worldwide rights to develop and market satraplatin

ND

NeoOncoRx intends to initiate Phase III studies for prostate cancer in early 2002 (9/7)

Neurochem Inc. (Canada; TSE:NRM)

Nycomed Amersham Imaging

Collaboration to create a diagnostic product for Alzheimer's disease

ND

The deal includes milestone payments to Neurochem, and royalties from a potential product (7/19)

Neurocrine Biosciences Inc. (NBIX)

GlaxoSmith-Kline plc (UK)

Research, development and commercialization agreement for corticotropin-releasing factor receptor antagonists 

$25.5

Neurocrine will receive up-front fees and early milestone payments totaling $25.5M, as well as annual fees and further milestone payments (7/24)

Norak Biosciences Inc.* 

Amersham Pharmacia Biotech Inc.

Collaboration in which Amersham will provide its LEADseeker Cell Analysis System and Norak will provide its Transfluor drug discovery technology

ND

The combination of the technologies has the potential to accelerate GPCR drug discovery (8/29)

Novasite Pharmaceuticals Inc. (subsidiary of Applied Molecular Evolution Inc.; AMEV)

Aventis Pharma AG (Germany)

Evaluation agreement to conduct a pilot screening project using Novasite's Expanded Target Drug Discovery technology platform

ND

Financial details were not disclosed (7/31)

Novirio Pharmaceuticals Ltd.*

Sumitomo Pharmaceuticals Co. Ltd. (Japan)

Development and distribution agreement for LdT for hepatitis B 

$46

Deal gives Sumitomo marketing rights to LdT in Japan, China, Taiwan and South Korea for $46M in up-front payments and milestones, as well as royalties (6/28)

Orion Corp. (Finland)*

Pharmacia Corp.

Agreement to collaborate in the development and commercialization of Orion Pharma's investigational new drug deramciclane in the U.S. 

$30

Orion Pharma, the pharmaceutical division of Orion Corp., will receive $30M up front, as well as milestone payments; Pharmacia holds the rights to develop and market deramciclane in countries outside the U.S. and Europe (8/27)

Peregrine Pharmaceuticals Inc. (PPHM)

Medipharm Biotech Co. (China)

Development agreement for Peregrine's tumor necrosis therapy

$1.8

Peregrine will provide product development and contract manufacturing services to Medipharm (9/6)

 Phytomedics Inc.*

 Bristol-Myers Squibb Co.

 Agreement to test the production of therapeutic proteins using Phytomedics' plant-based recombinant proteins secretion technology

ND

Phytomedics has been funding the development of the Repost technology at Rutgers University (9/17)

ProCorde GmbH (Germany)*

Aventis Pharma Deutschland GmbH (unit of Aventis SA; Germany)

Two-year cooperation agreement to identify new therapeutic target proteins for the development of pharmaceuticals for heart and vascular diseases

ND

ProCorde will receive a basic fee, as well as potential milestones (9/7)

Protein Design Labs Inc. (PDLI)

American Home Products Corp.

Two-year patent rights agreement for worldwide, nonexclusive rights for antibodies to a specific target antigen

ND

PDL will receive up-front license fees (7/11)

Qiagen NV (the Netherlands; QGENF)

Bayer AG (Germany)

Technology access and evaluation agreement involving the ZeptoGene Workstation technology platform

ND

Financial terms were not disclosed (8/7)

Questcor Pharmaceuticals Inc. (AMEX:QSC)

Fabre Kramer Pharmaceuticals Inc.

Agreement to pursue the worldwide development and commercialization of Hypnostat for insomnia and Panistat for  panic disorders

ND

The companies signed a letter of understanding and expect to form a joint venture, with Fabre Kramer providing the funding (6/27)

Rosetta Inpharmatics Inc. (RSTA) and Agilent Technologies Inc. (NYSE:A)

Monsanto Co.

Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System

ND

Financial terms were not disclosed (6/27)

RTP Pharma Inc. (Canada)*

Baxter Healthcare Corp.

Exclusive agreement to collaborate on the use of RTP's insoluble drug delivery technology for the formulation of injectable medications

ND

RTP will receive license fees, milestone payments and royalties on net sales of IDD-formulated injectable medications (9/18)

Sangamo BioSciences Inc. (SGMO)

Pharmacia Corp.

Agreement to develop cell lines for small-molecule screening

ND

Sangamo will receive up-front payments, research funding, product development milestones and royalties (7/17)

Seattle Genetics Inc. (SGEN)

CLB-Research and Development (the Netherlands)

Agreement to license certain monoclonal antibodies that target cancer and immunological disease

ND

Seattle Genetics will have development, manufacturing and worldwide commercialization rights to therapeutic products derived from the antibodies (7/18)

Sequenom Inc. (SQNM)

GlaxoSmith-Kline plc (UK)

Agreement to make 400,000 SNP assays available by the end of the year 

ND

GlaxoSmithKline will identify 50% of the SNP candidates, and Sequenom will select the other half; Sequenom retains commercial rights to the portfolio it generates, and Glaxo will pay money for access to the portfolio (8/29)

TransTech Pharma Inc.*

Novo Nordisk A/S (Denmark)

Five-year collaboration in which TransTech will use its Translational Technology to turn out clinical candidates from Novo's targets 

ND

TransTech will receive an up-front payment, as well as research support, milestones and royalty payments; Novo gets an exclusive worldwide license to certain realized products (8/6)

Tripos Inc. (TRPS)

Schering AG (Germany)

Agreement to build a global Enhanced Chemical Information Management System

ND

The system integrates Schering's compound research data and inventory data (9/6)

ViroPharma Inc. (VPHM)

Aventis Pharmaceuticals (U.S. division of Aventis Pharma AG; Germany)

Co-development and co-promotion agreement for Picovir 

$25

ViroPharma will receive $25M as an initial payment, plus undisclosed milestones for regulatory and other achievements; the companies will split profits from Picovir, if approved, with 55% going to Aventis and 45% going to ViroPharma (9/10)

Visible Genetics Inc. (Canada; VGIN)

Abbott Laboratories Inc. 

Agreement under which VGI will assist Abbott by providing HIV resistance testing in two clinical studies involving Kaletra

ND

VGI will use its Trugene HIV-1 genotyping system to perform genotype analysis, and will include the data from the study in its HIV drug resistance mutation database (7/16)

Vivalis (France)*

Aventis Pasteur (France)

Joint research program in the field of avian embryonic stem cells 

ND

The program allows an assessment of the ability of stem cells to be used in vaccine production (8/30)

Weston Medical Group plc (UK; LSE:WMG)

Abbott Laboratories Inc.

Agreement for an exclusive rights option to use the Intraject technology for up to 11 therapeutic targets in the next 10 years

ND

Weston would receive up-front fees, milestone payments and royalties (7/20)

XenoPharm Inc.*

Bristol-Myers Squibb Co.

XenoPharm will evaluate developmental compounds using proprietary assays

ND

XenoPharm will determine the compounds' ability to induce the expression of drug metabolism enzymes typically found in the liver (8/22)

XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL)

Dong-Wha Pharmaceutical Industrial Co. Ltd. (South Korea)

Collaboration to evaluate small-molecule compounds to treat hepatitis C 

ND

Dong-Wha will retain development and marketing rights in Korea; XTL has the option to acquire those rights in the rest of the world (7/19)

ZymoGenetics Inc.*

Serono SA (Switzerland)

Development and commercialization agreement for two preclinical product candidates, TACI and BCM 

$52.5

The companies will share research and development expenses worldwide, with the exception of Japan, where Serono will cover all expenses (9/4) 

NOTES

^# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange